Compare HSDT & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSDT | SCNI |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 4.6M |
| IPO Year | N/A | N/A |
| Metric | HSDT | SCNI |
|---|---|---|
| Price | $3.42 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 713.8K | 41.3K |
| Earning Date | 11-18-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $941,000.00 | ★ $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.13 | N/A |
| P/E Ratio | ★ N/A | $4.66 |
| Revenue Growth | 87.45 | ★ 303.87 |
| 52 Week Low | $2.83 | $0.86 |
| 52 Week High | $1,200.00 | $6.18 |
| Indicator | HSDT | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 55.65 |
| Support Level | $3.83 | $1.14 |
| Resistance Level | $4.32 | $1.30 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 22.13 | 76.16 |
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.